Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancer

Purpose

The objectives of this study were to determine whether the midazolam clearance predicted docetaxel pharmacokinetics, CA-125 change, and response and to assess the impact of cytochrome P450 (CYP) 3A5 and ATP-binding cassette, subfamily B, member 1 (ABCB1) genotypes on docetaxel pharmacokinetics and pharmacodynamics in ovarian or primary peritoneal cancer patients.

Methods

Thirty-four patients with advanced ovarian and primary peritoneal cancer were administered docetaxel at 75?mg/m² as a 1-h infusion in combination with carboplatin IV over 30?min at a target AUC of 5?mg/ml?min. Cycles were repeated every 21?days for 6 cycles. Midazolam was administered at 2?mg as a 30-min IV infusion the day prior to cycle one of docetaxel administration. Pharmacokinetic studies of docetaxel and CYP3A5 and ABCB1 genotype studies were performed.

Results

There was an inverse relationship between midazolam clearance (CL) and CA-125 level after cycle 6 where a higher midazolam CL was associated with a CA-125?<10?U/ml (P?=?0.007) and CA-125?<15?U/ml (P?=?0.048). The CA-125 categories were associated with response achieved (complete response/partial response) (CR/PR), stable disease (SD), and progressive disease (PD) at the end of therapy (P?=?0.0173). Docetaxel CL was not related to midazolam CL or genotype. Docetaxel exposure and genotypes were not related to toxicity or response (P?>?0.05).

Conclusions

The midazolam CL predicted CA-125 levels and response that was independent of other factors including docetaxel pharmacokinetics. Future studies need to evaluate the mechanism for the relationship between midazolam CL and response in patients with ovarian cancer.